STABILIZED PRE-FUSION RSV FB ANTIGENS

The present invention provides stable pre-fusion respiratory syncytial virus (RSV) FB proteins, nucleic acid molecules and vectors encoding such proteins, and compositions comprising said proteins, nucleic acid molecules and/or vectors, and uses thereof for the prevention and/or treatment of RSV inf...

Full description

Saved in:
Bibliographic Details
Main Authors RITSCHEL, Tina, BAKKERS, Mark Johannes Gerardus, LANGEDIJK, Johannes Petrus Maria
Format Patent
LanguageEnglish
Published 25.04.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention provides stable pre-fusion respiratory syncytial virus (RSV) FB proteins, nucleic acid molecules and vectors encoding such proteins, and compositions comprising said proteins, nucleic acid molecules and/or vectors, and uses thereof for the prevention and/or treatment of RSV infection.
Bibliography:Application Number: US202218546798